BioNTech expands global footprint by acquiring GMP manufacturing site to establish first mRNA facility in Singapore

• First mRNA manufacturing facility in Singapore will create regional manufacturing capacities in support of BioNTech’s growing pipeline of mRNA-based vaccines and therapeutics across Asia Pacific region for both clinical and commercial scale
• State-of-the art facility is expected to be fully operational in late 2023, and to create more than 100 jobs
• Acquisition marks the next step in BioNTech’s plans to establish a regional hub in the Asia Pacific Region
  

BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced its Singapore affiliate BioNTech Pharmaceuticals Asia Pacific Pte. Ltd. had entered into an agreement with Novartis Singapore Pharmaceutical Manufacturing Pte. Ltd. to acquire one of its GMP-certified manufacturing facilities. The acquisition is part of BioNTech’s expansion strategy to strengthen its global footprint in Asia. Supported by the Singapore Economic Development Board (“EDB”), the facility will serve as BioNTech’s Regional Headquarters and become its first mRNA manufacturing facility in Singapore.
 

BioNTech’s Singapore mRNA manufacturing facility will create regional manufacturing capacities in support of BioNTech’s growing pipeline of mRNA-based vaccines and therapeutics across Asia Pacific region for both commercial and clinical scale, with the potential to expand the production to other drug classes, such as cell therapies. The facility will be initially equipped to manufacture a range of mRNA-based product candidates as well as authorized vaccines and therapeutics for infectious diseases. This may include the Company’s COVID-19 vaccine, as well as oncology product candidates if successfully developed and approved or authorized by regulatory authorities.

The site will be a fully integrated mRNA manufacturing facility bringing mRNA production capabilities across drug substance and drug product, with an expected annual production capacity of up to several hundred million doses of mRNA-based vaccines after a full built-out. It is expected to create more than 100 jobs by 2024 in Singapore across multiple functions, including operations, engineering, quality, finance, human resources, as well as supply chain management, with recruiting starting immediately for first positions. The plant will be part of BioNTech’s affiliate BioNTech Pharmaceuticals Asia Pacific Pte. Ltd. and be fully integrated into the Company’s global manufacturing network.